Investing.com - LAVA Therapeutics NV reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
LAVA Therapeutics NV announced earnings per share of $0.04 on revenue of $15.26M. Analysts polled by Investing.com anticipated EPS of $-0.57 on revenue of $333.33K.
LAVA Therapeutics NV shares are down 12% from the beginning of the year and are trading at $4.80 , down-from-52-week-high.
LAVA Therapeutics NV follows other major Healthcare sector earnings this month
LAVA Therapeutics NV's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
Pfizer had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.78 on revenue of $22.6B, compared to forecast for EPS of $1.44 on revenue of $21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar